reason report
execut still new rep hire remain track pt
bottom line remain outperform given view
cologuard highli under-penetr strong
popul believ could deliv penetr
revenu longer term penetr
ttm sale recent analysi util leerink healthcar
advanc analyt suggest hire extern rep
remain track complet mid-august slightli
earlier timelin highlight compani
result rais revenu estim
estim price target move
extern sale rep key drive cologuard reorder rate
hire addit rep remain track reiter
call expect recruit addit intern
extern sale rep beyond exist sale forc hope
complet hire use leerink healthcar advanc
analyt identifi extern posit post may
steadili fill posit remain track
complet hire mid-august analysi present
note
appoint mark stenhous presid colorguard
central commerci sale forc strategi pcp reorder rate
believ wait recruit mark stenhous
mp launch next phase sale forc expans mr
stenhous join posit april come year
experi lead larg pharma commerci organ nation
sale team primari care immunology-gastroenterolog set
right execut view lead cologuard franchis
ultim desir penetr expand
patient popul includ year old believ sale
strategi remain critic cologuard expans longer term
see cologuard line primari care drug competit
except unpopular colonoscopi procedur
geograph distribut new rep suggest expand
next recogn major new sale rep posit
scatter across eastern posit west key
major metropolitan area extern sale rep alreadi place
join rank would surpris next bolu
sale rep expans happen westward also highlight analysi
note suggest like expand sale
forc remain key drive cologuard reorder rate reach
pcp broadli across countri ultim drive upsid estim
life scienc tool diagnost
combin sale dcf
net debt total capit
compani inform leerink partner llc research
revenu non-gaap ep exclud charg
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate outperform price target colorect cancer
larg grow market new diagnos death everi year
alon project annual cost accord expect
earli detect key surviv chanc surviv stage
result colorect screen market massiv patient strong consist
year old individu average-risk profil ac american cancer
societi recommend screen age extend year old averag risk
popul ad anoth patient ad potenti effort provid
non-invas test anoth high-risk patient alreadi undergo
colonoscopi plan trial high-risk indic colonoscopi consid
gold standard screen patient undergo colonoscopi leav
unscreen reli over-the-count test limit sensit
specif gener fear invas colonoscopi prep involv reduc patient
complianc leav mani patient slowli year inch toward stage
colon cancer odd surviv limit cologuard address
major unmet need market fda-approv medicar commerci cover
screen test non-invas high sensit specif
respect compar much cheaper over-the-count altern fecal
immunochem test fobt fecal occult blood test test cologuard also
recommend major clinic guidelin includ uspstf prevent servic task
alreadi instrument help cologuard gain commerci payer coverag
throughout result remain confid cologuard captur reach
overal screen patient popul market longer run around
recent sale expans recruit track
remain outperform given view cologuard highli under-penetr
long-term strong popul believ could deliv
penetr revenu longer term penetr ttm
call april reiter plan hire addit rep
util leerink healthcar advanc analyt identifi may alreadi
post job open specif target extern sale forc believ
posit fill believ hire extern sale
rep complet mid-august essenti within timelin state
compani us reflect manag execut paramount
share approv guidelin reimburs alreadi place cologuard
announc earlier januari expand sale forc extern
intern rep rep recal alreadi expand sale
forc intern extern sale rep believ rep fulli
product take month rep product though number could
lower certain rep given exist primari care physician relationship territori
reiter call expect hire addit intern extern
sale rep beyond exist sale forc hope complet hire
util leerink healthcar advanc analyt could see steadili hire
extern sale rep posit remain track view complet hire
mid-august extern sale rep greatest interest investor essenti
drive reorder rate gener much easier hire intern call center sale forc
somewhat experienc extern sale forc scatter geograph key
figur post extern sale rep posit around may start
fill posit steadili rep hire data analysi suggest recruit
complet mid-august continu onboard batch like
continu earli
leerink healthcar advanc analyt leerink equiti research estim compani websit
onboard batch
also believ onboard new rep batch expect
process continu earli gener take month accord get
rep fulli product believ gain signific experi recruit
onboard rep reduc time even experi best practic
drug industri incorpor mark stenhous leadership believ
rep like reach product sooner rather later give confid
growth assumpt outlook cologuard longer term onboard
rep batch base convers manag reflect time would
take hire rep believ onboard could continu earli expect
rep fulli product nine month contribut significantli beyond
mark stenhous bring signific commerci experi
believ wait recruit mark stenhous launch next
phase sale forc expans mr stenhous join compani april year
presid cologuard year sale experi primari care immunology-
gastroenterolog set right execut view lead cologuard franchis
ultim desir penetr expand patient popul includ
expand indic year old longer term mr stenhous respons
lead cologuard commerci function includ sale market commerci
oper believ remain central cologuard expans longer term see
cologuard line primari care drug competit except unpopular
colonoscopi procedur still standard care
mr stenhous respons manag larg sale forc rose rank
year led humira franchis believ goal mind
hire mr stenhous onto teamour view increas sale forc
headcount leadership capabl manag much larger sale forc
current
recogn cologuard mono-ind product vs multi-ind product
humira mr stenhous leadwhich like requir sophist multi-
specialti sale approach believ enhanc commerci team experi
drive penetr higher among pcp ob/gyn nurs practition
continu see primari care physician adopt cologuard give tool lack
beforeespeci rural counti gastrointestin gi physician easili
access also recogn shortag gi physician countri highlight
number medacorp network
hire remain track complet
employ leerink healthcar advanc analyt review sale rep hire time
take reach target headcount figur extern sale rep need hire sale
rep drive reorder rate better serv new exist account
accord analysi alreadi hire current target number
new extern rep end june current hire rate lead us believ
conclud hire extern rep sometim late around mid-august
believ safe assum model new rep ad end
also use leerink healthcar advanc analyt look back past hire pattern includ
extern sale rep hire hire pattern suggest hire tick
posit complet fill match manag
comment prior call
figur extern sale rep open subsequ hire rep
declin peak point posit fill
leerink healthcar advanc analyt leerink research compani websit
geograph distribut open suggest hire
use leerink healthcar advanc analyt platform abl better understand exass
hire statu growth strategi relat geograph facet commerci plan
analysi help us identifi locat current hire show us
current fill posit shown figur clear current plan
deploy new extern sale rep heavili eastern us addit key major
citi recal alreadi sale rep place across countri
extern sale rep expans ad
figur geograph distribut recent extern sale rep hire
leerink healthcar advanc analyt leerink research compani websit
view like add futur sale rep western us regard
opportun one recent report issu cdc center diseas control percentag
respond age report date colorect cancer screen
heavili skew eastern western show consider lower
complianc repres larg untap opportun broad
potenti rural area believ mani patient unlik travel long distanc undertak
procedur colonoscopi much alon awar screen
view could target patient group easili via pcp group like
amen conveni altern colonoscopy-bas screen believ
drive adopt higher beyond recent rate healthcar effect data
inform set hedi measur incentiv physician increas rate screen
within hospit system also recal alreadi expand effort medic
educ medic liaison team place also drive cologuard adopt higher
reach larg hospit system rais larg hospit system sale forc
last quartersinclud two physician team well
figur percent popul date screen state yellow
blue area repres higher complianc screen
center diseas control
extern rep drive cologuard reorder rate
view revenu growth depend fast compani hire sale rep
turn drive new physician reorder catalyz growth exist physician
order typic new physician cautiou adopt cologuard screen method
patient colonoscopi alway gold standard
histor seen new prescrib order around one cologuard per quarter number
increas new physician becom educ product far
sale rep serv far mani pcp current extern sale
rep serv physician thu rep serv averag physician
continu non-respond rep hire faster abl reach
new pcp aggress abl serv exist account sooner and/or
frequent primari care physician becom comfort cologuard place
colonoscopi screen tool physician like prescrib mani his/her
patient second-lin altern socjust seen last medacorp
physician dinner physician order close cologuard quarter
figur estim peak sale rep product suggest signific
room sale rep product expans
accord manag goal cologuard market adopt expect
penetr screen market longer term exass market share
come pcp expect continu come prescrib primari care
set current around pcp alon nurs practition ob/gyn
gastroenterologist rais number closer accord studi biopharma
allianc pcp refus sale rep visit pcp refer no-se eighti
percent no-se categor no-se choic institution/practic ban
sale rep visit without physician choic twenti percent no-se categor
no-se choic mean no-se pcp chosen refus sale rep visit
studi note no-se choic group would open sale rep visit
institution/practic allow see rep go forward expect unabl
reach pcp consid no-se creat penetr pcp popul
around pcp open sale rep visit
conserv scenario analysi suggest upsid
also construct rel conserv scenario analysi assess impact/benefit
addit field sale rep per year bring total
believ conserv scenario rep addit could significantli higher
cologuard becom name everi primari care physician recogn like
prescrib believ mark stenhous commerci organ potenti deliv
longer term assum current annual annual rep product assess long-term
upsid revenu ep believ conserv measur rep
product rise overtim hard identifi upper boundlik drive
estim even higher strongli believ get signific upsid scale
rep longer term concurr expans insid sale rep much easier hire
gross volum visit annual per routin visit pcp annual per pcp visit annual per rep need servic everi patient includ address per year patient screen everi product per visit per day per exact scienc corpor
figur conduct rel conserv scenario analysi assess
impact revenu ep addit sale rep per year
estim still look conserv us focu
remain guid
compani guid test perform expect test
reach upper rang guid test perform compar street
conserv around test investor may recal setback flu season
test volum drop believ test volum growth return normal harsh flu
season sentiment support confid guid also note
histor season better quarter year believ
case model project revenu approxim
versu street estim approxim expect investor focu remain
full-year guid oper flu concern past manag
view recent sale forc hire
total extern sale addit sale rep per revenu revenu addit revenu profit sale rep net incom revenu upsid ep upsid except share sale rep ep assum concurr increas insid sale rep exact scienc corpor
new ac screen recommend like take
rememb ac american cancer societi updat guidelin recommend
colorect cancer screen age vs ac design recommend
qualifi strong manag suggest us earlierac
recommend automat translat uspstf nation comprehens
cancer network nccn recommend age new limit assum uspstf
includ year old timelin uspstf meet
spoke medacorp specialist directli involv model ac
guidelin screen medacorp specialist notic risk increas
time younger patient hypothes risk may carri forward throughout patient
life specialist note evalu perform way uspstf look
benefit burden ratio burden express term number colonoscopi
need per lifetim conclus studi begin screen posit
benefit/burden ratio specialist also note uspstf doesnt pure look cost
rather cost effect screen
accord medacorp specialist consensu among scientist physician
current inclus year age believ trial might need support
inclus new age limit uspstf model data might enough
strongli believ diagnost compani relev experi personnel
potenti undertak studi like littl incent other run trial
evalu benefit/burden ratio screen year old note earliest could
implement like uspstf meet next
ultim believ uspstf could adopt standard believ take time
implement could expand total address market patient averag
risk patient ad potenti addit revenu note ac histor
influenc uspstf guidelin recogn signific ac
recommend uspstf meet everi year nation comprehens cancer
liver data look promis highlight potenti
recal exass deliv impress earli detect liver test data digest diseas week
ddw recent review dr john kisiel mayo clinic present phase ii liver
data senior academ medacorp hepatologistwho call marker data impress
expect test receiv approv continu sensit stage
detect matter vs current standard test involv ultrasound
afp alfa-fetoprotein afp rel cheap test deliv poor perform earli
detect hepatocellular carcinoma exactli liver test deliv
see market opportun longer term earli detect surveil
believ test could launch laboratori develop test ldt file
fda approv test
target sale strategi cologuard continu
goal extern sale forc reach target account insid sale forc
call new provid educ cologuard recal market sale
strategi uniqueexa spend tv advertis social media digit platform
initi reach patient believ spend also like increas reach
broadli frequent patient across countri
figur cologuard market sale strategi
patient educ risk acknowledg need undergo
screen either talk pcp colonoscopi point assum
pcp like prescrib colonoscopi bring cologuard ask pcp
cologuard point ball physician court whether prescrib
cologuard physician choos prescrib cologuard notifi
compani send repres educ physician product familiar
doctor benefits/risk establish initi relationship also ping patient
let know cologuard way ask question relat
process patient receiv order collect sampl ship back
screen later rep visit doctor follow see physician
addit question extern sale team spend lot time
process crux drive reorder rate patient physician
becom awar procedur viabil screen tool becom easier
market could potenti chang standard care
given size opportun limit penetr surpris see
trade ev/sal turn higher high growth med-tech group
trade ev/sal trade
twice small-cap diagnost averag ev/sal valu use
combin ev/sal dcf analysi better valu high-growth long-run
characterist view use wacc beta long-term growth rate
ebit margin equiti risk premium believ long-term
growth rate conserv estim given nearli half popul still remain
unscreen us popul could rise intern patient also includ
pool ev/sal multipl result price target dcf analysi yield
price target given higher growth rate outer year expand target
penetr expand patient popul averag ev/sal
multipl dcf analysi
risk valuat
primari risk price target includ limit worse-than-
expect penetr cologuard better sensit test develop
fda regul ldt test right includ lung pancreat test
reduct reimburs rate given polit factor facil audit citat
would halt cologuard test temporarili revers posit decis pa
possibl cologuard reach servic market target despit encourag
sign number public sensit effect rel non-
test competitor could develop enhanc sensit compet cologuard
mani gener fobt test compet cologuard serv non-invas
screener gener altern cologuard develop greater sensit
believ would risk downsid given cologuard price
gener test differ price peopl will pay like declin gap
cologuard competitor narrow current also blood base test
epi procolon appli proteom volit rx look compet non-invas
screen market well howev current studi show cologuard current best
non-invas option screen base sensit specif
fda regul remain risk regulatori concern fda decis
impact test still earli stage develop lung pancreat
esophag cancer diagnost test could impact fda fda regul
could impact develop product time commerci clinic trial
certain test increas regul fda requir addit sg expens
satisfi complianc increas cost could also affect abil market product
brand public health educ product
decreas reimburs would present downsid risk estim current
reimburs rate cologuard project medicar propos protect
access medicar act pama commerci contract come near well
much revenu base reimburs rate medicar impact
number test administ adopt rate exist new test cologuard ramp
would sever impact reimburs rate fell recent polit risk involv new
medicar polici could potenti impact reimburs rate would signific
effect cologuard test well
profit could delay also partner mayo foundat sinc
januari enter agreement mayo pay mayo low-
singl digit royalti net sale product mayo name includ cologuard
expect royalti expens categor cog addit pay
mayo instal cash newer studi and/or addit
royalti could delay profit longer initi expect
good sold
sg sale
 sale
oper expens sale
compani report leerink partner estim
